Zeitschrift für Hämatologie und thromboembolische Erkrankungen
Offener Zugang

Abstrakt

Role of Anticoagulation in COVID-19 Treatment

Prasanna Kattekola

Coronavirus Disease 2019 (COVID-19) is caused by a novel coronavirus (SARS-CoV2) and is a highly contagious disease that first appeared in Wuhan, Hubei province of China in December 2019. Many nations are battling to control the spread of the infection. In the infected population, although most of the patients have mild symptoms of fever, fatigue and cough, in some severe cases, patients can progress rapidly and develop the acute respiratory distress syndrome, metabolic acidosis, septic shock, and coagulopathy, venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC). This article focuses on the emerging guidelines and various recommendations of different institutions on how to manage thrombotic risk, coagulopathy and DIC in patients with COVID-19. The data presented below is intended to provide guidance for anticoagulation prophylaxis and treatment in COVID-19 patients and should not supersede clinical judgement.